Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Biosergen AB (DE:8N1)
:8N1
Holding DE:8N1?
Track your performance easily
8N1 Stock Chart & Stats
Day’s Range― - ―
52-Week Range€0.02 - €0.09
Previous CloseN/A
Volume0.00
Average Volume (3M)5.00
Market Cap
€9.96M
Enterprise Value€76.33M
Total Cash (Recent Filing)$589.00K
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
Beta-0.58
Next Earnings
Mar 31, 2025Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.02
Shares Outstanding234,823,210
10 Day Avg. Volume0
30 Day Avg. Volume5
Standard DeviationN/A
R-SquaredN/A
AlphaN/A
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)N/A
P/FCF Ratio0.00
Enterprise Value/Market Cap7.67
Enterprise Value/Revenue28.18
Enterprise Value/Gross Profit-428.82
Enterprise Value/Ebitda-2.24
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
Biosergen AB News
8N1 FAQ
What was Biosergen AB’s price range in the past 12 months?
Biosergen AB lowest stock price was €0.02 and its highest was €0.09 in the past 12 months.
What is Biosergen AB’s market cap?
Biosergen AB’s market cap is €9.96M.
When is Biosergen AB’s upcoming earnings report date?
Biosergen AB’s upcoming earnings report date is Mar 31, 2025 which is in 66 days.
How were Biosergen AB’s earnings last quarter?
Biosergen AB released its earnings results on Nov 29, 2024. The company reported €0 earnings per share for the quarter, the consensus estimate of €0 by €0.
Is Biosergen AB overvalued?
According to Wall Street analysts Biosergen AB’s price is currently Overvalued.
Does Biosergen AB pay dividends?
Biosergen AB does not currently pay dividends.
What is Biosergen AB’s EPS estimate?
Biosergen AB’s EPS estimate is 0.
How many shares outstanding does Biosergen AB have?
Biosergen AB has 234,823,210 shares outstanding.
What happened to Biosergen AB’s price movement after its last earnings report?
Biosergen AB reported an EPS of €0 in its last earnings report, expectations of €0. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Biosergen AB?
Currently, no hedge funds are holding shares in DE:8N1
---
Company Description
Biosergen AB
Biosergen AB is a biotech company developing innovative antifungal drugs based on latest biopharmaceutical research and development from laboratory facilities in Trondheim, Norway and several other places worldwide. It is developing BSG005, a potentially disruptive antifungal drug, which has demonstrated significant safety and potency advantages over competing antifungals.
---
Technical Analysis
---